Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias

Heart Rhythm

Volumn 3, Issue 8, 2006, Pages 948-956

  Liu, Tengxian ^a   Brown, Barry S ^b   Wu, Ying ^a   Antzelevitch, Charles ^c   Kowey, Peter R ^a,d   Yan, Gan Xin ^a,d  

^a Main Line Health Heart Center   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Arrhythmia; Ion Channels; Long QT Syndrome; Myocytes; Sudden Cardiac Death

Indexed keywords

AZITHROMYCIN; CAPTOPRIL; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; DESIPRAMINE; ERYTHROMYCIN; FEXOFENADINE; MOXIFLOXACIN; SPARFLOXACIN; TERFENADINE; THIORIDAZINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY PERFUSION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE; ISOLATION PROCEDURE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QUANTITATIVE ANALYSIS; RABBIT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TORSADE DES POINTES; VALIDATION PROCESS;

ACTION POTENTIALS; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART CONDUCTION SYSTEM; PERFUSION; PREDICTIVE VALUE OF TESTS; RABBITS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TORSADES DE POINTES; VENTRICULAR FUNCTION, LEFT;

EID: 33746294441     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2006.04.021     Document Type: Article

References (47)

1. Selzer A., and Wray H.W. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
2. Joshi A., DiMino T., Vohra Y., Cui C., and Yan G.X. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs. the role of experimental models. J Electrocardiol 37 Suppl (2004) 7-14
3. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., and Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs. evidence for a provisional safety margin in drug development. Cardiovasc Res 58 (2003) 32-45
4. Milberg P., Ramtin S., Monnig G., Osada N., Wasmer K., Breithardt G., Haverkamp W., and Eckardt L. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol 44 (2004) 278-286
5. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs. is QT prolongation really the problem?. J Electrocardiol 37 Suppl (2004) 15-24
6. Shimizu W., Ohe T., Kurita T., Kawade M., Arakaki Y., Aihara N., Kamakura S., Kamiya T., and Shimomura K. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 26 (1995) 1299-1309
7. Yan G.X., Wu Y., Liu T., Wang J., Marinchak R.A., and Kowey P.R. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome. Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103 (2001) 2851-2856
8. Lankipalli R.S., Zhu T., Guo D., and Yan G.X. Mechanisms underlying arrhythmogenesis in long QT syndrome. J Electrocardiol 38 Suppl (2005) 69-3
9. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24 (2003) 619-625
10. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. Nonclinical proarrhythmia models. predicting Torsades de Pointes. J Pharmacol Toxicol Methods 52 (2005) 46-59
11. Yan G.X., and Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 93 (1996) 372-379
12. Yan G.X., Shimizu W., and Antzelevitch C. The characteristics and distribution of M cells in arterially-perfused canine left ventricular wedge preparations. Circulation 98 (1998) 1921-1927
13. Yan G.X., and Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100 (1999) 1660-1666
14. Yan G.X., Joshi A., Guo D., Hlaing T., Martin J., Xu X., and Kowey P.R. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation 110 (2004) 1036-1041
15. Shimizu W., and Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 35 (2000) 778-786
16. Nam G.B., Burashnikov A., and Antzelevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 111 (2005) 2727-2733
17. Chen X., Cass J.D., Bradley J.A., Sun Z., and Zhou J. Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs. J Pharmacol Toxicol Methods (2006) in press
18. Arellano-Rodrigo E., Garcia A., Mont L., and Roque M. [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome]. Med Clin (Barc) 117 (2001) 118-119
19. Slater J.W., Zechnich A.D., and Haxby D.G. Second-generation antihistamines. a comparative review. Drugs 57 (1999) 31-47
20. Doig J.C. Drug-induced cardiac arrhythmias. incidence, prevention and management. Drug Saf 17 (1997) 265-275
21. Shah R.R. Drug-induced prolongation of the QT interval. regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16 (2002) 147-156
22. Moller M., Torp-Pedersen C.T., and Kober L. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congest Heart Fail 7 (2001) 146-150
23. Lehmann M.H., Hardy S., Archibald D., Quart B., and Macneil D.J. Sex difference in risk of torsade de pointes with d,I-sotalol. Circulation 94 (1996) 2535-2541
24. Bauman J.L., Bauernfeind R.A., Hoff J.V., Strasberg B., Swiryn S., and Rosen K.M. Torsade de pointes due to quinidine. Observations in 31 patients. Am Heart J 107 (1984) 425-430
25. Cavero I., and Crumb W. Moving towards better predictors of drug-induced Torsade de Pointes. Expert Opin Drug Saf 5 (2006) in press
26. + currents of epicardial and endocardial myocytes in rabbits. Circulation 103 (2001) 1585-1590
27. Lu H.R., Remeysen P., Somers K., Saels A., and De Clerck F. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 12 (2001) 538-545
28. Fossa A.A., Depasquale M.J., Raunig D.L., Avery M.J., and Leishman D.J. The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J Pharmacol Exp Ther 302 (2002) 828-833
29. Champeroux P., Viaud K., El Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., and Richard S. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol 144 (2005) 376-385
30. Gintant G.A., Limberis J.T., McDermott J.S., Wegner C.D., and Cox B.F. The canine Purkinje fiber. an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37 (2001) 607-618
31. Antzelevitch C., Sun Z.Q., Zhang Z.Q., and Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT and torsade de pointes. J Am Coll Cardiol 28 (1996) 1836-1848
32. Yan G.X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
33. Mattioni T.A., Zheutlin T.A., Sarmiento J.J., Parker M., Lesch M., and Kehoe R.F. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med 111 (1989) 574-580
34. Di Diego J.M., Belardinelli L., and Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108 (2003) 1027-1033
35. Dhar S., Hazra P.K., Malakar S., and Mistri G. Fexofenadine-induced QT prolongation. a myth or fact?. Br J Dermatol 142 (2000) 1260-1261
36. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs. importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol 41 (2003) 14-24
37. Hondeghem L.M., Lu H.R., van Rossem K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart. blinded validation. J Cardiovasc Electrophysiol 14 (2003) 287-294
38. Hondeghem L.M., Carlsson L., and Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103 (2001) 2004-2013
39. Antzelevitch C., Davidenko J.M., Sicouri S., et al. Electrophysiologic effects of quinidine in canine Purkinje fibers and ventricular myocardium. Slow development of the antiarrhythmic and arrhythmogenic effects of the drug. In: Velasco M., Israel A., Romero E., and Silva H. (Eds). Recent Advances in Pharmacology and Therapeutics (1989), Ecerpta Medica, New York 259-263
40. Clifford C.P., Adams D.A., Murray S., Taylor G.W., Wilkins M.R., Boobis A.R., and Davies D.S. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 52 (1997) 311-315
41. Kang J., Wang L., Chen X.L., Triggle D.J., and Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Molec Pharmacol 59 (2001) 122-126
42. Drugdex Drug Evaluation. In: Klasco R.K. (Ed). Physician's Desk Reference Online (2005), Thomson Micromedex, Colorado
43. Stanat S.J., Carlton C.G., Crumb Jr. W.J., Agrawal K.C., and Clarkson C.W. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 254 (2003) 1-7
44. Lacerda A.E., Kramer J., Shen K.Z., Thomas D., and Brown A.M. Comaprison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J Supplements 3 Supple K (2001) K23-K30
45. Kongsamut S., Kang J., Chen X.L., Roehr J., and Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450 (2002) 37-41
46. Zhang S., Zhou Z., Gong Q., Makielski J.C., and January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84 (1999) 989-998
47. Warner B., and Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 21 (2002) 189-203